Form 4: ANI Pharma SVP Sells Shares Under 10b5-1 Plan

Chad Gassert, SVP of Corporate Development and Strategy at ANI Pharmaceuticals Inc., sold common stock totaling 14,736 shares in two transactions in November 2025.

Summary

• Chad Gassert, SVP of Corporate Development and Strategy for ANI Pharmaceuticals Inc. (ANIP), reported the sale of common stock.
• The transactions occurred on November 12, 2025, and November 13, 2025.
• On November 12, 2025, Gassert disposed of 14,642 shares of common stock at a weighted average price of $89.07 per share.
• On November 13, 2025, an additional 94 shares of common stock were sold at a price of $88.00 per share.
• The sales were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these transactions, Gassert indirectly beneficially owns 158,490 shares of common stock held by Chali Properties LLC, over which he holds voting and dispositive power.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that it was conducted under a Rule 10b5-1 plan suggests it was pre-scheduled for personal financial planning rather than a reaction to new company-specific information, thus mitigating potential negative interpretations.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, which suggests the transactions were pre-planned and not based on new, non-public information, potentially mitigating concerns about insider selling.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a desire for diversification by management.

Risks

• Market perception of insider selling could lead to short-term negative sentiment towards ANI Pharmaceuticals Inc. shares.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly sales, are common occurrences in publicly traded companies. When conducted under a Rule 10b5-1 plan, they are generally viewed as part of an executive's personal financial planning, such as diversification or liquidity needs, rather than a direct signal about the company's immediate prospects. Many executives establish such plans to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing a structured approach for insiders to trade company securities while mitigating potential insider trading concerns.

Corporate Governance

Related Party Transactions

• The shares are indirectly held by Chali Properties LLC, over which the reporting person, Chad Gassert, holds voting and dispositive power, indicating a related party holding.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan typically lessens concerns about management's confidence in the company's future.
• Employees and other stakeholders might monitor insider transactions for insights into executive sentiment.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Chad Gassert, Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, Common Stock